Translational Cancer Research

投稿咨询

官方网站：http://tcr.amegroups.com/

投稿网址：http://tcr.amegroups.com/login?source=%2Fauthor%2Fsubmit

PMC链接：http://www.ncbi.nlm.nih.gov/nlmcatalog?term=2218-676X%5BISSN%5D

转化性癌症研究（Transl Cancer Res-TCR；印刷ISSN:2218-676X；在线ISSN 2219-6803；www.the tcr.org）是一个开放的、同行评审的期刊，由AME出版公司出版，发表了连接实验室和临床环境的新型研究调查结果，包括风险评估、细胞和分子。以提高癌症患者临床护理水平为总体目标，对人类癌症进行定性、预防、检测、诊断和治疗。TCR将公布新的治疗干预措施的实验室研究以及评估癌症新治疗模式的临床试验。TCR的重点是原始的、同行评审的、基于科学的研究，该研究成功地将临床医学推向改善癌症患者生活的目标。编辑和一个由科学家和临床医生科学家以及其他专家组成的国际咨询小组将把TCR文章保持在高质量标准。我们接受原创文章以及评论文章、社论和简短文章。香港翻译癌症研究学会官方刊物。

Translational Cancer Research (Transl Cancer Res TCR; Print ISSN: 2218-676X; Online ISSN 2219-6803; www.thetcr.org) is an Open Access, peer-reviewed journal, published by AME Publishing Company, publishes the results of novel research investigations which bridge the laboratory and clinical settings including risk assessment, cellular and molecular characterization, prevention, detection, diagnosis and treatment of human cancers with the overall goal of improving the clinical care of cancer patients. TCR will publish laboratory studies of novel therapeutic interventions as well as clinical trials which evaluate new treatment paradigms for cancer. The focus of TCR is original, peer-reviewed, science-based research that successfully advances clinical medicine toward the goal of improving cancer patients lives. The editors and an international advisory group of scientists and clinician-scientists as well as other experts will hold TCR articles to the high-quality standards. We accept Original Articles as well as Review Articles, Editorials and Brief Articles. The Official Publication of Society for Translational Cancer Research (STCR),Hong Kong